Actively Recruiting
PET Imaging CCR2 in Lung Inflammation
Led by Washington University School of Medicine · Updated on 2026-05-01
110
Participants Needed
1
Research Sites
513 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.
CONDITIONS
Official Title
PET Imaging CCR2 in Lung Inflammation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day and have smoked at least 100 cigarettes over the past month
- Screening FEV1 and FVC greater than 80% of predicted
- Able to lie still and supine within the PET/CT and PET/MR scanner for about 1 hour and follow breathing instructions during the CT
- No illicit or inhaled drug use within the past year
- No known history of cardiac, pulmonary, hepatic or renal disease or diabetes
- No claustrophobia or other conditions preventing completion of imaging sessions
- Able to understand and willing to follow study procedures
- Body mass index (BMI) less than or equal to 35
You will not qualify if you...
- Currently enrolled in another study using an investigational drug
- Pregnancy confirmed by urine test
- Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes
- Currently taking any prescription medications
- Presence of implanted devices incompatible with CT or MRI scanning
- Creatinine over 1.30 mg/dL, AST over 50 Units/L, ALT over 55 Units/L, or total bilirubin over 1.2 mg/dL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
S
Steven Brody, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here